Primary central nervous system germ cell tumors. Effect of histologic confirmation on radiotherapy. 1988

C R Kersh, and W C Constable, and D R Eisert, and C A Spaulding, and S S Hahn, and J M Jenrette, and R D Marks
Division of Therapeutic Radiology and Oncology, University of Virginia Medical Center, Charlottesville 22908.

Primary malignant intracranial germ cell tumors are rare lesions responsible for only 0.5% of all central nervous system (CNS) malignancy. With stereotactic localization these lesions can be safely biopsied, and histologic confirmation will affect the ultimate prognosis. This report is a multi-institutional retrospective analysis of 33 patients diagnosed with a primary CNS germ cell tumor. Tumors in 14 patients (42%) were histologically confirmed (13 germinoma and one embryonal cell carcinoma); 19 patients were treated with a presumptive diagnosis. All patients were irradiated with a dose range of 3950 cGy to 6000 cGy to the primary lesions. Eight patients received craniospinal irradiation, and 25 patients were locally treated. The 5-year actuarial survival for the entire population was 64%. The survival rate in patients with histologic confirmation was 79% versus 53% in the unbiopsied population. Radiation doses greater than 5000 cGy, radiotherapy volume, and age were prognostic factors in determining survival.

UI MeSH Term Description Entries
D010871 Pinealoma Neoplasms which originate from pineal parenchymal cells that tend to enlarge the gland and be locally invasive. The two major forms are pineocytoma and the more malignant pineoblastoma. Pineocytomas have moderate cellularity and tend to form rosette patterns. Pineoblastomas are highly cellular tumors containing small, poorly differentiated cells. These tumors occasionally seed the neuroaxis or cause obstructive HYDROCEPHALUS or Parinaud's syndrome. GERMINOMA; CARCINOMA, EMBRYONAL; GLIOMA; and other neoplasms may arise in the pineal region with germinoma being the most common pineal region tumor. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2064; Adams et al., Principles of Neurology, 6th ed, p670) Neoplasms, Pineal,Pineal Neoplasms,Pinealocytoma,Pineoblastoma,Pineocytoma,Mixed Pineocytoma-Pineoblastoma,Pineal Gland Tumor,Pineal Parenchymal Tumors,Pineal Tumors,Mixed Pineocytoma Pineoblastoma,Mixed Pineocytoma-Pineoblastomas,Neoplasm, Pineal,Pineal Gland Tumors,Pineal Neoplasm,Pineal Parenchymal Tumor,Pineal Tumor,Pinealocytomas,Pinealomas,Pineoblastomas,Pineocytoma-Pineoblastoma, Mixed,Pineocytoma-Pineoblastomas, Mixed,Pineocytomas,Tumor, Pineal,Tumor, Pineal Gland,Tumor, Pineal Parenchymal,Tumors, Pineal,Tumors, Pineal Gland,Tumors, Pineal Parenchymal
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D004407 Dysgerminoma A malignant ovarian neoplasm, thought to be derived from primordial germ cells of the sexually undifferentiated embryonic gonad. It is the counterpart of the classical seminoma of the testis, to which it is both grossly and histologically identical. Dysgerminomas comprise 16% of all germ cell tumors but are rare before the age of 10, although nearly 50% occur before the age of 20. They are generally considered of low-grade malignancy but may spread if the tumor extends through its capsule and involves lymph nodes or blood vessels. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1646) Disgerminoma,Disgerminomas,Dysgerminomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D001706 Biopsy Removal and pathologic examination of specimens from the living body. Biopsies
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

C R Kersh, and W C Constable, and D R Eisert, and C A Spaulding, and S S Hahn, and J M Jenrette, and R D Marks
December 2003, Current treatment options in oncology,
C R Kersh, and W C Constable, and D R Eisert, and C A Spaulding, and S S Hahn, and J M Jenrette, and R D Marks
January 1997, Neurologia (Barcelona, Spain),
C R Kersh, and W C Constable, and D R Eisert, and C A Spaulding, and S S Hahn, and J M Jenrette, and R D Marks
August 2010, Journal of neurosurgery. Pediatrics,
C R Kersh, and W C Constable, and D R Eisert, and C A Spaulding, and S S Hahn, and J M Jenrette, and R D Marks
March 2002, Current treatment options in neurology,
C R Kersh, and W C Constable, and D R Eisert, and C A Spaulding, and S S Hahn, and J M Jenrette, and R D Marks
April 1998, Seminars in oncology,
C R Kersh, and W C Constable, and D R Eisert, and C A Spaulding, and S S Hahn, and J M Jenrette, and R D Marks
October 2004, Seminars in oncology,
C R Kersh, and W C Constable, and D R Eisert, and C A Spaulding, and S S Hahn, and J M Jenrette, and R D Marks
March 2018, Medical research archives,
C R Kersh, and W C Constable, and D R Eisert, and C A Spaulding, and S S Hahn, and J M Jenrette, and R D Marks
January 1992, Journal of neuro-oncology,
C R Kersh, and W C Constable, and D R Eisert, and C A Spaulding, and S S Hahn, and J M Jenrette, and R D Marks
December 2005, No to shinkei = Brain and nerve,
C R Kersh, and W C Constable, and D R Eisert, and C A Spaulding, and S S Hahn, and J M Jenrette, and R D Marks
January 2022, Frontiers in oncology,
Copied contents to your clipboard!